Reslizumab

Drug Profile

Reslizumab

Alternative Names: Anti-interleukin-5 monoclonal antibody - Celltech/Schering-Plough; CDP 835; CEP-38072; CINQAERO; CINQAIR; Cinquil; CTx 55700; DCP 835; SCH 5570; SCH 55700; TRFK-5

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Celltech R&D; Schering-Plough
  • Developer Celltech R&D; Teva Pharmaceutical Industries
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophagitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Phase III Sinusitis
  • No development reported Oesophagitis

Most Recent Events

  • 03 Mar 2017 Updated pooled efficacy data from two phase III trials in Asthma presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
  • 16 Feb 2017 Teva Pharmaceutical plans a phase III trial for Asthma (NCT03052725)
  • 18 Aug 2016 Registered for Asthma in Liechtenstein, Iceland, Norway, European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top